Skip to main content

Advertisement

SpringerLink
Log in

Rituximab in children with steroid sensitive nephrotic syndrome: in quest of the optimal regimen

  • Educational Review
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Rituximab has emerged as an effective and important therapy in children with complicated frequently relapsing and steroid-dependent nephrotic syndrome to induce long-term disease remission and avoid steroid toxicities. The optimal rituximab regimen is not totally well defined, and there are many varying practices worldwide. We will in this review describe how patient factors, rituximab dose, and use of maintenance immunosuppression affect treatment outcomes. Specifically, low-dose rituximab without concomitant immunosuppression is associated with shorter relapse-free duration while other regimens have comparable outcomes. Patients with more severe disease generally have worse response to rituximab. Although rituximab appears to be generally safe, there are growing concerns of chronic hypogammaglobulinemia and impaired immunity especially in young children. Reliable prognostications and biomarkers for guiding subsequent treatments to avoid excessive treatments are yet to be identified. In this review, we will outline the, as we see it, best approach of rituximab in childhood steroid sensitive nephrotic syndrome at the present state of knowledge.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Chanchlani R, Parekh RS (2016) Ethnic differences in childhood nephrotic syndrome. Front Pediatr 4:39

    PubMed  PubMed Central  Google Scholar 

  2. Webb N, Woolley R, Lambe T, Frew E, Brettell E, Barsoum E, Trompeter R, Cummins C, Deeks J, Wheatley K (2019) Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: phase III randomised controlled trial and economic evaluation. Bmj 365:I1800

    Google Scholar 

  3. Iijima K, Sako M, Nozu K (2017) Rituximab for nephrotic syndrome in children. Clin Exp Nephrol 21(2):193–202

    CAS  PubMed  Google Scholar 

  4. Benz K, Dötsch J, Rascher W, Stachel D (2004) Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 19(7):794–797

    PubMed  Google Scholar 

  5. Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y (2014) Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. The Lancet 384(9950):1273–1281

    CAS  Google Scholar 

  6. Ravani P, Rossi R, Bonanni A, Quinn RR, Sica F, Bodria M, Pasini A, Montini G, Edefonti A, Belingheri M (2015) Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial. J Am Soc Nephrol 26(9):2259–2266

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Ruggenenti P, Ruggiero B, Cravedi P, Vivarelli M, Massella L, Marasà M, Chianca A, Rubis N, Ene-Iordache B, Rudnicki M (2014) Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol 25(4):850–863

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Basu B, Sander A, Roy B, Preussler S, Barua S, Mahapatra T, Schaefer F (2018) Efficacy of rituximab vs. tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: a randomized clinical trial. JAMA Pediatr 172(8):757–764

    PubMed  PubMed Central  Google Scholar 

  9. Prytuła A, Iijima K, Kamei K, Geary D, Gottlich E, Majeed A, Taylor M, Marks SD, Tuchman S, Camilla R (2010) Rituximab in refractory nephrotic syndrome. Pediatr Nephrol 25(3):461–468

    PubMed  Google Scholar 

  10. Deschênes G, Vivarelli M, Peruzzi L (2017) Variability of diagnostic criteria and treatment of idiopathic nephrotic syndrome across European countries. Eur J Pediatr 176(5):647–654

    PubMed  Google Scholar 

  11. Kamei K, Ogura M, Sato M, Sako M, Iijima K, Ito S (2016) Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab. Pediatr Nephrol 31(1):89–95

    PubMed  Google Scholar 

  12. Ito S, Kamei K, Ogura M, Udagawa T, Fujinaga S, Saito M, Sako M, Iijima K (2013) Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome. Pediatr Nephrol 28(2):257–264

    PubMed  Google Scholar 

  13. Ito S, Kamei K, Ogura M, Sato M, Fujimaru T, Ishikawa T, Udagawa T, Iijima K (2011) Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol 26(10):1823–1828

    PubMed  Google Scholar 

  14. Sinha A, Bhatia D, Gulati A, Rawat M, Dinda AK, Hari P, Bagga A (2014) Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome. Nephrol Dial Transpl 30(1):96–106

    Google Scholar 

  15. Kemper MJ, Gellermann J, Habbig S, Krmar RT, Dittrich K, Jungraithmayr T, Pape L, Patzer L, Billing H, Weber L (2011) Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transpl 27(5):1910–1915

    Google Scholar 

  16. Chan EY-H, Webb H, Yu E, Ghiggeri GM, Kemper MJ, Ma AL-T, Yamamura T, Sinha A, Bagga A, Hogan J (2020) Both the rituximab dose and maintenance immunosuppression in steroid-dependent/frequently-relapsing nephrotic syndrome have important effects on outcomes. Kidney Int 97(2):393–401

    CAS  PubMed  Google Scholar 

  17. Fujinaga S, Hirano D, Mizutani A, Sakuraya K, Yamada A, Sakurai S, Shimizu T (2017) Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment. Clin Exp Nephrol 21(4):671–676

    CAS  PubMed  Google Scholar 

  18. Hogan J, Dossier C, Kwon T, Macher M-A, Maisin A, Couderc A, Niel O, Baudouin V, Deschênes G (2018) Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 34(2):253–259

    PubMed  Google Scholar 

  19. Ahn YH, Kim SH, Han KH, Choi HJ, Cho H, Lee JW, Shin JI, Cho MH, Lee JH, Park YS (2018) Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea. Medicine (Baltimore) 97(46)

  20. Webb H, Jaureguiberry G, Dufek S, Tullus K, Bockenhauer D (2016) Cyclophosphamide and rituximab in frequently relapsing/steroid-dependent nephrotic syndrome. Pediatr Nephrol 31(4):589–594

    PubMed  Google Scholar 

  21. Maxted AP, Dalrymple RA, Chisholm D, McColl J, Tse Y, Christian MT, Reynolds BC (2019) Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome. Pediatr Nephrol 34(5):855–863

    PubMed  Google Scholar 

  22. Basu B, Mahapatra T, Mondal N (2015) Mycophenolate mofetil following rituximab in children with steroid-resistant nephrotic syndrome. Pediatrics 136(1):e132–e139

    PubMed  Google Scholar 

  23. Fujinaga S, Someya T, Watanabe T, Ito A, Ohtomo Y, Shimizu T, Kaneko K (2013) Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab. Eur J Pediatr 172(4):513–518

    CAS  PubMed  Google Scholar 

  24. Horinouchi T, Sako M, Nakanishi K, Ishikura K, Ito S, Nakamura H, Oba MS, Nozu K, Iijima K (2018) Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07). BMC nephrol 19(1):302

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Bonanni A, Calatroni M, D'alessandro M, Signa S, Bertelli E, Cioni M, Di Marco E, Biassoni R, Caridi G, Ingrasciotta G (2018) Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome. Br J Clin Pharmacol 84(6):1238–1249

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Parmentier C, Delbet J-D, Decramer S, Boyer O, Hogan J, Ulinski T (2019) Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol 35(3):455–462

    PubMed  Google Scholar 

  27. Fujinaga S, Sakuraya K, Yamada A, Urushihara Y, Ohtomo Y, Shimizu T (2015) Positive role of rituximab in switching from cyclosporine to mycophenolate mofetil for children with high-dose steroid-dependent nephrotic syndrome. Pediatr Nephrol 30(4):687–691

    PubMed  Google Scholar 

  28. Kamei K, Ogura M, Sato M, Ito S, Ishikura K (2018) Infusion reactions associated with rituximab treatment for childhood-onset complicated nephrotic syndrome. Pediatr Nephrol 33(6):1013–1018

    PubMed  Google Scholar 

  29. Tsutsumi Y, Kanamori H, Mori A, Tanaka J, Asaka M, Imamura M, Masauzi N (2005) Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 4(3):599–608

    CAS  PubMed  Google Scholar 

  30. Chaumais M-C, Garnier A, Chalard F, Peuchmaur M, Dauger S, Jacqz-Agrain E, Deschênes G (2009) Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol 24(9):1753–1755

    PubMed  Google Scholar 

  31. Boren EJ, Cheema GS, Naguwa SM, Ansari AA, Gershwin ME (2008) The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun 30(1-2):90–98

    CAS  PubMed  Google Scholar 

  32. Gea-Banacloche JC (2010) Rituximab-associated infections. Seminars in hematology 47(2):187–198

    CAS  PubMed  Google Scholar 

  33. Sellier-Leclerc A-L, Belli E, Guérin V, Dorfmüller P, Deschênes G (2013) Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome. Pediatr Nephrol 28(9):1875–1879

    PubMed  Google Scholar 

  34. Sato M, Ito S, Ogura M, Kamei K, Miyairi I, Miyata I, Higuchi M, Matsuoka K (2013) Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome. Pediatr Nephrol 28(1):145–149

    PubMed  Google Scholar 

  35. Kamei K, Takahashi M, Fuyama M, Saida K, Machida H, Sato M, Ogura M, Ito S (2014) Rituximab-associated agranulocytosis in children with refractory idiopathic nephrotic syndrome: case series and review of literature. Nephrol Dial Transpl 30(1):91–96

    Google Scholar 

  36. Peuvrel L, Chiffoleau A, Quéreux G, Brocard A, Saint-Jean M, Batz A, Jolliet P, Dréno B (2013) Melanoma and rituximab: an incidental association? Derm 226(3):274–278

    CAS  Google Scholar 

  37. Velter C, Pagès C, Schneider P, Osio A, Brice P, Lebbé C (2014) Four cases of rituximab-associated melanoma. Melanoma Res 24(4):401–403

    PubMed  Google Scholar 

  38. Tarella C, Passera R, Magni M, Benedetti F, Rossi A, Gueli A, Patti C, Parvis G, Ciceri F, Gallamini A (2010) Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol 29(7):814–824

    PubMed  Google Scholar 

  39. Colucci M, Carsetti R, Serafinelli J, Rocca S, Massella L, Gargiulo A, Lo Russo A, Capponi C, Cotugno N, Porzio O (2019) Prolonged impairment of immunological memory after anti-CD20 treatment in pediatric idiopathic nephrotic syndrome. Front Immunol 10:1653

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Wijetilleka S, Jayne DR, Mukhtyar C, Ala A, Bright PD, Chinoy H, Harper L, Kazmi MA, Kiani-Alikhan S, Li CK (2019) Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases. Rheumatology 58(5):889–896

    CAS  PubMed  Google Scholar 

  41. Kamei K, Ishikura K, Sako M, Aya K, Tanaka R, Nozu K, Kaito H, Nakanishi K, Ohtomo Y, Miura K (2017) Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab. Pediatr Nephrol 32(11):2071–2078

    PubMed  Google Scholar 

  42. Basu B, Sander A, Preussler S, Sinha Mahapatra T, Schaefer F (2019) IPN11036-82 Long-term efficacy of rituximab & MMF maintenance - therapy in childhood SDNS. Abstracts of the 18th Congress of the International Pediatric Nephrology Association, Venice (Italy), October 2019. Pediatr Nephrol 34:1821–2260. https://doi.org/10.1007/s00467-019-04325-4

    Article  Google Scholar 

  43. Kim JH, Park E, Hyun HS, Cho MH, Ahn YH, Choi HJ, Kang HG, Ha I-S, Cheong HI (2017) Long-term repeated rituximab treatment for childhood steroid-dependent nephrotic syndrome. Kidney Res Clin Pract 36(3):257

    PubMed  PubMed Central  Google Scholar 

  44. Ramachandran R, Bharati J, Rao I, Kashif AW, Nada R, Minz R, Gupta KL, Kohli HS (2019) Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy. Nephrology (Carlton) 24(12):1241–1247

    CAS  Google Scholar 

  45. Delbet JD, Leclerc G, Ulinski T (2019) Idiopathic nephrotic syndrome and rituximab: may we predict circulating B lymphocytes recovery? Pediatr Nephrol 34(3):529–532

    PubMed  Google Scholar 

  46. Sato M, Kamei K, Ogura M, Ishikura K, Ito S (2018) Relapse of nephrotic syndrome during post-rituximab peripheral blood B-lymphocyte depletion. Clin Exp Nephrol 22(1):110–116

    CAS  PubMed  Google Scholar 

  47. Colucci M, Corpetti G, Emma F, Vivarelli M (2018) Immunology of idiopathic nephrotic syndrome. Pediatr Nephrol 33(4):573–584

    PubMed  Google Scholar 

  48. Colucci M, Carsetti R, Cascioli S, Serafinelli J, Emma F, Vivarelli M (2019) B cell phenotype in pediatric idiopathic nephrotic syndrome. Pediatr Nephrol 34(1):177–181

    PubMed  Google Scholar 

  49. Colucci M, Carsetti R, Cascioli S, Casiraghi F, Perna A, Ravà L, Ruggiero B, Emma F, Vivarelli M (2016) B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome. J Am Soc Nephrol 27(6):1811–1822

    CAS  PubMed  Google Scholar 

  50. Kimata T, Hasui M, Kino J, Kitao T, Yamanouchi S, Tsuji S, Kaneko K (2013) Novel use of rituximab for steroid-dependent nephrotic syndrome in children. Am J Npehrol 38(6):483–488

    CAS  Google Scholar 

  51. Takahashi T, Okamoto T, Sato Y, Yamazaki T, Hayashi A, Aoyagi H, Ueno M, Kobayashi N, Uetake K, Nakanishi M (2019) Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study. Pediatr Nephrol 34(1):87–96

    PubMed  Google Scholar 

  52. Ahn YH, Kang HG, Lee JM, Choi HJ, Ha I-S, Cheong HI (2014) Development of antirituximab antibodies in children with nephrotic syndrome. Pediatr Nephrol 29(8):1461–1464

    PubMed  Google Scholar 

  53. Chan C-Y, Liu ID, Resontoc LP, Ng K-H, Chan Y-H, Lau PY-W, Than M, Jordan SC, Lam K-P, Yeo W-S (2016) T lymphocyte activation markers as predictors of responsiveness to rituximab among patients with FSGS. Clin J Am Soc Nephrol 11(8):1360–1368

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Paediatric Nephrology, Great Ormond Street Hospital for Children NHS Trust, London, UK

    Eugene Yu-hin Chan & Kjell Tullus

  2. Paediatric Nephrology Centre, Hong Kong Children’s Hospital, Kowloon, Hong Kong

    Eugene Yu-hin Chan

Authors
  1. Eugene Yu-hin Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kjell Tullus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eugene Yu-hin Chan.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chan, E.Yh., Tullus, K. Rituximab in children with steroid sensitive nephrotic syndrome: in quest of the optimal regimen. Pediatr Nephrol 36, 1397–1405 (2021). https://doi.org/10.1007/s00467-020-04609-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-020-04609-0

Keywords

Search

Navigation